The current Egrifta SV and Egrifta WR labels specify once-daily administration. Their dosage sections do not require bedtime dosing or a two-hour fast. A claim that those rules are mandated by the FDA label is incorrect.
What the product labels actually say about timing
| Product | Labeled frequency and amount | Preparation timing | Source |
|---|---|---|---|
| Egrifta SV | 1.4 mg once daily | Administration immediately after reconstitution; unused solution is discarded. | Egrifta SV label, sections 2.1-2.2 |
| Egrifta WR | 1.28 mg once daily | One reconstituted vial provides seven daily doses, with product-specific storage instructions. | Egrifta WR label, sections 2.1-2.2 |
The names refer to different formulations. A general article about tesamorelin cannot substitute one product's preparation or storage instructions for another's. The earlier version of this page mixed a 2 mg dose, a bedtime rule and refrigerated storage into a single supposed label instruction; that combination is not what these labels say.
Does the growth-hormone mechanism prove bedtime works better?
A physiological explanation and a product instruction are different forms of evidence. To show that an evening schedule works better than a morning schedule, the relevant evidence would be a direct comparison of those schedules with a defined formulation and clinical endpoint. Neither of the dosage sections linked above establishes such a comparison.
Does the label require an empty stomach?
The dosage sections do not specify a two-hour fasting window. That rule should not be presented as a quoted or implied FDA instruction. Individual instructions from a prescriber should be distinguished from the published product label.
From the FormBlends catalog
Tesamorelin
GHRH analog studied for visceral-fat reduction; the molecule was approved as Egrifta · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Tesamorelin →Why does the vial amount differ from the labeled dose?
A vial's total contents and the amount administered at one time are separate quantities. Product name, vial presentation and administered dose should be read together, rather than treating every tesamorelin vial as the same product.
Frequently asked questions
Morning or night?
The cited labels establish once-daily frequency, not a required morning or night window.
Can the SV storage instructions be used for WR?
The products have different preparation and storage systems. Use the instructions for the exact formulation.
Related resources
Platform. FormBlends is an educational science writing platform. Nothing on this page constitutes medical advice, a diagnosis, or a treatment recommendation. Consult a licensed prescriber before using any peptide or hormone product.
Research Compound or Compounded Medication. Tesamorelin (Egrifta) is an FDA-approved prescription drug for HIV-associated lipodystrophy. Compounded tesamorelin exists in the marketplace and is subject to varying regulatory status depending on jurisdiction and compound classification. Off-label use should be supervised by a qualified physician.
Results. Clinical results described on this page are from published trials in specific populations (primarily HIV-positive adults with lipodystrophy). Results in other populations may differ and have not been established in large RCTs. Individual results vary.
Trademark. Egrifta and Egrifta SV are registered trademarks of Theratechnologies Inc. FormBlends has no affiliation with Theratechnologies Inc. or any tesamorelin manufacturer.
Ready when you are
Tesamorelin
GHRH analog studied for visceral-fat reduction; the molecule was approved as Egrifta · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Tesamorelin →